Cancer scientists point finger at T4 & RT3 hormones

Page 3: References

Back to main article, Page 1, Page 2

Bolger, M. B., & Jorgensen, E. C. (1980). Molecular interactions between thyroid hormone analogs and the rat liver nuclear receptor. Partitioning of equilibrium binding free energy changes into substituent group interactions. The Journal of Biological Chemistry, 255(21), 10271–10278.

Burman, K. D., Dimond, R. C., Wright, F. D., Earll, J. M., Bruton, J., & Wartofsky, L. (1977). A radioimmunoassay for 3,3’,5’-L-triiodothyronine (reverse T3): Assessment of thyroid gland content and serum measurements in conditions of normal and altered thyroidal economy and following administration of thyrotropin releasing hormone (TRH) and thyrotropin (TSH). The Journal of Clinical Endocrinology and Metabolism, 44(4), 660–672.

Busnardo, B., Girelli, M. E., Bui, F., Zanatta, G. P., & Cimitan, M. (1980). Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment. Journal of Endocrinological Investigation, 3(4), 353–356.

Busnardo, B., Bui, F., & Girelli, M. E. (1983). Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: Effect of an optimal saturation regimen with thyroxine or triiodothyronine. Journal of Endocrinological Investigation, 6(6), 455–461.

Celi, F. S., Zemskova, M., Linderman, J. D., Babar, N. I., Skarulis, M. C., Csako, G., … Pucino, F. (2010). The pharmacodynamic equivalence of levothyroxine and liothyronine. A randomized, double blind, cross-over study in thyroidectomized patients. Clinical Endocrinology, 72(5), 709–715.

Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., … Pucino, F. (2011). Metabolic effects of liothyronine therapy in hypothyroidism: A randomized, double-blind, crossover trial of liothyronine versus levothyroxine. The Journal of Clinical Endocrinology and Metabolism, 96(11), 3466–3474.

Chopra, I. J., Solomon, D. H., & Teco, G. N. C. (1973). Thyroxine: Just a Prohormone or a Hormone Too? The Journal of Clinical Endocrinology & Metabolism, 36(6), 1050–1057.

Dayan, C. M., & Panicker, V. (2009). Interpretation of Thyroid Function Tests and Their Relationship to Iodine Nutrition-Chapter 5:Changes in TSH, Free T4, and Free T3 Resulting from Iodine Deficiency and Iodine Excess. In Comprehensive Handbook of Iodine (pp. 47–54). Elsevier Inc.

Davis, P. J., & Davis, F. B. (1996). Nongenomic actions of thyroid hormone. Thyroid: Official Journal of the American Thyroid Association, 6(5), 497–504.

Davis, F. B., Tang, H.-Y., Shih, A., Keating, T., Lansing, L., Hercbergs, A., Fenstermaker, R. A., Mousa, A., Mousa, S. A., Davis, P. J., & Lin, H.-Y. (2006). Acting via a Cell Surface Receptor, Thyroid Hormone Is a Growth Factor for Glioma Cells. Cancer Research, 66(14), 7270–7275.

Fiore, E., & Vitti, P. (2012). Serum TSH and Risk of Papillary Thyroid Cancer in Nodular Thyroid Disease. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1134–1145.

Führer, D., Bockisch, A., & Schmid, K. W. (2012). Euthyroid Goiter With and Without Nodules—Diagnosis and Treatment. Deutsches Ärzteblatt International, 109(29–30), 506–516.

Green, W. L. (1968). Guidelines for the Treatment of Myxedema. Medical Clinics of North America, 52(2), 431–450.

Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011). Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE, 6(8).

Hercbergs, A. A., Goyal, L. K., Suh, J. H., Lee, S., Reddy, C. A., Cohen, B. H., Stevens, G. H., Reddy, S. K., Peereboom, D. M., Elson, P. J., Gupta, M. K., & Barnett, G. H. (2003). Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study. Anticancer Research, 23(1B), 617–626.

Hercbergs, A. (2019). Clinical Implications and Impact of Discovery of the Thyroid Hormone Receptor on Integrin αvβ3–A Review. Frontiers in Endocrinology, 10.

Hercbergs, A., Johnson, R. E., Ashur-Fabian, O., Garfield, D. H., & Davis, P. J. (2015). Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: An observational study. The Oncologist, 20(1), 72–76.

Hercbergs, A., Davis, P. J., Lin, H.-Y., & Mousa, S. A. (2016). Possible contributions of thyroid hormone replacement to specific behaviors of cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 84, 655–659.

Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013). Desiccated Thyroid Extract Compared With Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-Blind, Crossover Study. The Journal of Clinical Endocrinology & Metabolism, 98(5), 1982–1990.

Hoermann, R., Midgley, J. E. M., Giacobino, A., Eckl, W. A., Wahl, H. G., Dietrich, J. W., & Larisch, R. (2014). Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. Clinical Endocrinology, 81(6), 907–915.

Hoermann, R., Pekker, M. J., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2020). Triiodothyronine secretion in early thyroid failure: The adaptive response of central feedforward control. European Journal of Clinical Investigation, 50(2), e13192.

Lin, H.-Y., Tang, H.-Y., Shih, A., Keating, T., Cao, G., Davis, P. J., & Davis, F. B. (2007). Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids, 72(2), 180–187.

Lin, H.-Y., Tang, H.-Y., Leinung, M., Mousa, S. A., Hercbergs, A., & Davis, P. J. (2019). Action of Reverse T3 on Cancer Cells. Endocrine Research, 1–5.

Midgley, J. E. M., Larisch, R., Dietrich, J. W., & Hoermann, R. (2015). Variation in the biochemical response to l-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency. Endocrine Connections, 4(4), 196–205.

Peeters, R. P., & Visser, T. J. (2017). Metabolism of Thyroid Hormone. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J. E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D. L. Trence, … D. P. Wilson (Eds.), Endotext., Inc.

Peeters, R. P., Wouters, P. J., van Toor, H., Kaptein, E., Visser, T. J., & Van den Berghe, G. (2005). Serum 3,3′,5′-Triiodothyronine (rT3) and 3,5,3′-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. The Journal of Clinical Endocrinology & Metabolism, 90(8), 4559–4565.

Selenkow, H. A., & Rose, L. I. (1976). Comparative clinical pharmacology of thyroid hormones. Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics, 1(3), 331–349.

Refetoff, S. (1975). Thyroid Hormone Therapy. Medical Clinics of North America, 59(5), 1147–1162.

Robinson, P. (2018). Recovering with T3. Elephant In the Room Books.

Wiersinga, W. M. (1979). The peripheral conversion of thyroxine into triiodothyronine (T3) and reverse triiodothyronine (rT3) (PhD, University of Amsterdam). Retrieved from

Yavuz, S., Linderman, J. D., Smith, S., Zhao, X., Pucino, F., & Celi, F. S. (2013). The Dynamic Pituitary Response to Escalating-Dose TRH Stimulation Test in Hypothyroid Patients Treated With Liothyronine or Levothyroxine Replacement Therapy. The Journal of Clinical Endocrinology & Metabolism, 98(5), E862–E866.

Pages: 1 2 3

Categories: Cancers, T4 hormone

Leave a public reply here, on our website.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: